SPIREs: A new horizon for allergic disease treatment?

Expert Review of Clinical Immunology

Volumn 11, Issue 11, 2015, Pages 1173-1175

  Worm, Margitta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

allergy; IgG4; mechanism; specific immunotherapy; synthetic peptides

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; EPITOPE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; PLACEBO; SYNTHETIC PEPTIDE; SYNTHETIC PEPTIDE CONSIST OF IMMUNOREGULATORY EPITOPE; UNCLASSIFIED DRUG; PEPTIDE;

ALLERGIC DISEASE; ALLERGIC REACTION; AMINO ACID SEQUENCE; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; LONG TERM CARE; MAST CELL DEGRANULATION; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOCONJUNCTIVITIS; SENSITIZATION; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; ANIMAL; ART; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; PEPTIDES; PORTRAITS AS TOPIC; T-LYMPHOCYTES;

EID: 84945133369     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1066673     Document Type: Review

References (20)

1. Aït-Khaled N, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009;64(1):123-48
2. Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases. Curr Opin Pharmacol 2014;17:30-7
3. Li JT, Lockey RF, Bernstein I, et al. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003;90(1 Suppl 1):1-40
4. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol 2012;12:249-56
5. Calderon MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:30-8
6. Calderon M, Mösges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010;65:420-34
7. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24
8. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
9. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120: 1338-45
10. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Data-base Syst Rev 2010(12):CD002893
11. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003 (2):CD002893
12. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T cell epitope containing peptides. Am J Respir Crit Care Med 1996;154:1623-8
13. Verhoef A, Alexander C, Kay AB, Larché M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2(3):e78
14. Larche M. Immunotherapy with Allergen Peptides. Allergy Asthma Clin Immunol 2007;3:53-9
15. Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206:1535
16. Larche M, Moldavar D. Immunotherapy with Peptides. Allergy 2011;66:784-91
17. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127: 89-97
18. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131(1):103-9
19. Hafner R, Couroux P, Armstrong K, et al. Two year persistent treatment effect achieved after 4 doses of cat-peptide antigen desensitization in an EEC model of cat allergy. J Allergy Clin Immunol 2013;131: AB147
20. Couroux P, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015;45(5): 974-81